Subtle cognitive decline on longitudinal testing in preclinical Alzheimer’s disease


  • Subtle cognitive decline increases the risk of disease progression in clinically normal (CN) adults with increased amyloid-β (Aβ+).

Why this matters

  • There is a need to establish clinically meaningful outcome measures in secondary prevention trials to minimize cognitive decline in asymptomatic individuals at-risk of developing Alzheimer’s disease (AD).

  • In the future, longitudinal testing of subtle cognitive decline could serve as a proxy for AD progression and functional decline in secondary prevention trials.